Plain-English translation of NCT06733038 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding , an immunotherapy medication, to a standard chemotherapy combination (called FOLFOXIRI plus ) can help people with advanced colorectal cancer live longer and have better outcomes. You would receive induction treatment (the intensive phase) for up to 8 cycles, followed by maintenance treatment (a lighter dose) until your cancer progresses or you experience unacceptable side effects.
Standard chemotherapy has helped many patients with advanced colorectal cancer, but doctors want to know if adding immunotherapy—which helps your immune system fight cancer—can improve results even further for certain patients whose tumors have specific characteristics.
You likely qualify if…
You likely don't qualify if…
You would visit a cancer center every two weeks to receive intravenous (IV) infusions of the study medications. The intensive treatment phase lasts up to 8 cycles (about 4 months), followed by a lighter maintenance phase that continues until your cancer progresses. You'll have regular blood tests and imaging scans to monitor how you're responding, and your medical team will closely watch for side effects throughout your participation.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
Italy